Mangoceuticals (MGRX) EBIT (2023 - 2026)

Mangoceuticals has disclosed EBIT across 4 years of filings, most recently posting -$1.0 million for Q2 2026.

• In Q2 2026, EBIT rose 80.39% year-over-year to -$1.0 million; the TTM figure through Jun 2026 stood at -$12.1 million (up 9.12% YoY), while the FY2025 annual figure was -$18.0 million, down 126.2% from the prior year.
• EBIT came in at -$1.0 million for Q2 2026 at Mangoceuticals, up from -$3.1 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$367739.0 in Q4 2025 to a low of -$7.5 million in Q3 2025.
• Average EBIT over 4 years is -$2.8 million, with a median of -$2.3 million recorded in 2023.
• Year-over-year, EBIT slumped 329.04% in 2025 and surged 80.39% in 2026.
• Over 4 years, EBIT stood at -$2.6 million in 2023, then surged by 34.67% to -$1.7 million in 2024, then surged by 78.08% to -$367739.0 in 2025, then sank by 180.92% to -$1.0 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$1.0 million in Q2 2026, -$3.1 million in Q1 2026, and -$367739.0 in Q4 2025.